0.00Open4.00Pre Close0 Volume25 Open Interest11.00Strike Price0.00Turnover0.00%IV220.51%PremiumDec 20, 2024Expiry Date0.00Intrinsic Value100Multiplier-3DDays to Expiry4.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma1.17Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Fulcrum Therapeutics Stock Discussion
Fulcrum Therapeutics Announces Topline Results from Phase 3 REACH Clinical Trial of Losmapimod in Facioscapulohumeral Muscular Dystrophy (FSHD)
Fulcrum Therapeutics (NASDAQ: FULC) announced that its Phase 3 REACH trial for losmapimod in Facioscapulohumeral Muscular Dystrophy (FSHD) failed to meet its primary endpoint. The trial showed no significant improvement in relative surface area (RSA) compared to placebo at week 48. Secondary endpoints also failed to ...
Fulcrum Therapeutics Enters Into a Collaboration and License Agreement With Sanofi for the Development and Commercialization of Losmapimod in Facioscapulohumeral Muscular Dystrophy
No comment yet